

ENANTA PHARMACEUTICALS INC
Form 8-K/A
November 24, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 24, 2014**

ENANTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35839

04-3205099

**(State or other jurisdiction
of incorporation)**

**(Commission File
Number)**

**(IRS Employer
Identification No.)**

500 Arsenal Street, Watertown, Massachusetts 02472

(Address of principal executive offices and zip code)

(617) 607-0800

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 9.01 Financial Statements and Exhibits.

The Form 8-K is amended to replace Exhibit 99.1 with the corrected version attached hereto, which is the version that was circulated to the press before the filing of the Form 8-K.

(d) Exhibits

Exhibit

| No. | Description |
|------------|---|
| 99.1 | Press Release of Enanta Pharmaceuticals, Inc., dated November 24, 2014, reporting Enanta's financial results for the fiscal fourth quarter and year ended September 30, 2014. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 24, 2014

ENANTA PHARMACEUTICALS, INC.

By: /s/ Paul J. Mellett
Paul J. Mellett

Senior Vice President, Finance and

Administration and Chief Financial Officer

EXHIBIT INDEX

Exhibit

| No. | Description |
|------------|---|
| 99.1 | Press Release of Enanta Pharmaceuticals, Inc., dated November 24, 2014, reporting Enanta's financial results for the fiscal fourth quarter and year ended September 30, 2014. |